OMER · Omeros Corporation

Current Thesis

OMER's two transformative binaries have already detonated: the Novo Nordisk asset deal for zaltenibart/OMS906 (announced 2025-10-15, +181% overnight; closed 2025-12-01 with $240M cash upfront) and the FDA approval of YARTEMLEA (narsoplimab-wuug) for TA-TMA on 2025-12-23, the first and only approved therapy in that indication. The 6x advance from ~$3 to $17.65 is in the rear-view. What trades today (~$10.74, roughly -39% off the high) is a one-quarter-old commercial launch ramp plus a floating next binary the EMA/CHMP opinion expected mid-2026. This is post-climax consolidation, not an accelerating leg. Probe-grade only until the ramp re-accelerates (Q2 print) or the EU decision lands.

Bull Case

• Balance sheet de-risked and durable. $135.3M cash/investments at 2026-03-31; the $17.1M 2026 notes were repaid at maturity (Feb 2026), leaving only $70.8M of 2029 convertibles (due June 2029). The going-concern overhang that pinned the stock near $3 is gone that structural re-rate is the real engine behind the double-digit handle.
• Novo Nordisk validation plus royalty optionality. Deal closed 2025-12-01: $240M cash paid, up to $340M near-term milestones (≈$100M still eligible), up to $2.1B total plus tiered royalties on the PNH program. Novo funds and runs the global Phase 3 OMER keeps blockbuster royalty upside without carrying the burn.
• First-and-only label in a fatal orphan setting. YARTEMLEA (FDA 2025-12-23) has no on-label competitor in TA-TMA; complement-orphan pricing economics. Q1 2026 gross $11.1M / net $9.9M (reported ~2026-05-14) is a clean Quarter-1 base.
• EU catalyst still ahead. The YARTEMLEA MAA was validated mid-2025; a CHMP opinion/EMA decision is expected mid-2026 a label-expansion catalyst inside the dossier horizon.
• Sell-side hasn't faded it. Strong Buy consensus (2026-04-02); 12-mo targets $32.50–$40.33 vs ~$10.74 spot.

Bear Case

• The move already happened. Down ~39% from $17.65, months of sideways digestion, euphoria bled off. For a momentum book this is the wrong phase the catalysts that powered the 6x are already spent.
• Headline "profit" is accounting. Q1 2026 net income of $56.1M / $0.78 EPS leans on a $73.1M non-cash mark-to-market gain on the 2029 notes' embedded derivative; strip it and operations still lose money on $9.9M of sales. Q4 2025's profit similarly rode the ~$237.6M one-time Novo transaction gain.
• Ultra-orphan ceiling. TA-TMA is a narrow HSCT-complication population; one quarter at $9.9M proves nothing about durable ramp slope, and a fast plateau is the base-rate risk for orphan launches.
• Squeeze DNA cuts both ways. 52-wk range $2.95→$17.65 with documented StockTwits attention into FDA dates; any launch miss opens air pockets quickly.
• Convertible noise. The 2029 derivative makes "EPS beats" non-comparable to operating beats and carries a dilution path.

Setup & Price Structure

• Last print ~$10.74 (2026-06-04, +5.71% on the day); mcap ~$777M; up ~300% YoY. 52-wk range $2.95–$17.65.
• Structure is post-climax consolidation: a vertical FDA/deal-driven advance that topped at $17.65, then a multi-month base. Working floor near $8.50; overhead supply into the ~$13–14 shelf. The single-day pop on 2026-06-04 is range noise, not a trend change.
• A weekly close back above ~$13–14 on expanding volume would mark the base resolving higher; a weekly close losing $8.50 says the consolidation is failing.
• Strength is absent here, so there is no momentum confirmation to buy. The only reason to engage is the launch ramp plus the EU binary, sized as a probe chasing intraday pops inside the base is the trap.

Catalyst Calendar (next 30 days)

• EMA/CHMP opinion on the YARTEMLEA TA-TMA MAA expected mid-2026, exact CHMP meeting date unconfirmed (CHMP sessions cluster around the third week of each month; a June ~2026-06-23/26 or a July session is the live window). This is the only near-term hard binary; a positive opinion is the upgrade trigger.
• Novo near-term milestones (~$100M still eligible) no scheduled date; payment or disclosure could print at any time as PNH program steps clear.
• Q2 2026 earnings est. mid-August 2026 (outside the 30-day window); blackout ~3 trading days prior. This is the ramp-proof number versus the $9.9M Q1 base.
• No OMER earnings within the next 3 trading days as of 2026-06-07.

What Would Change Our Mind

• Upgrade to HIGH on any of: a positive CHMP/EMA opinion on the TA-TMA MAA; Q2 2026 net sales materially above the $9.9M Q1 base (ramp confirmed); or a weekly breakout above ~$13–14 on volume.
• Thesis breaks / stay sidelined on: a weekly close below $8.50 (consolidation floor lost); Q2 2026 net sales ≤ $9.9M (flat/down = ramp stalled); or a negative CHMP opinion.
• Sizing discipline: binary with retail-squeeze DNA keep any engagement small until a hard catalyst or ramp datapoint is in hand.

Correlation Notes

• Idiosyncratic, low macro beta the tape runs on FDA/EMA events and launch-ramp prints, not rates or SPY/QQQ. On risk-on days the name correlates to small-cap biotech sentiment (XBI), amplified by its squeeze DNA.
• Partner read-through: zaltenibart/OMS906 royalty optionality ties part of the long-tail upside to Novo Nordisk (NVO) executing the PNH Phase 3.
• Peer complex for sentiment and comps: complement and rare-disease names Apellis (APLS), the broader complement-inhibitor space, and legacy Alexion (now within AstraZeneca). Watch XBI for the small-cap biotech regime backdrop.